Literature DB >> 24969012

Multicriteria decision analysis in the reimbursement of new medical technologies: real-world experiences from Hungary.

Dóra Endrei1, Bálint Molics2, István Agoston2.   

Abstract

Mesh：

Year:  2014        PMID： 24969012     DOI： 10.1016/j.jval.2014.01.011

Source DB:  PubMed          Journal:  Value Health        ISSN： 1098-3015            Impact factor:   5.725


× No keyword cloud information.
  15 in total

1.  Comparative analysis of decision maker preferences for equity/efficiency attributes in reimbursement decisions in three European countries.

Authors:  Petra Baji; Manuel García-Goñi; László Gulácsi; Emmanouil Mentzakis; Francesco Paolucci
Journal:  Eur J Health Econ       Date:  2015-08-22

2.  Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria.

Authors:  László Gulácsi; Alexandru M Rotar; Maciej Niewada; Olga Löblová; Fanni Rencz; Guenka Petrova; Imre Boncz; Niek S Klazinga
Journal:  Eur J Health Econ       Date:  2014-05-16

Review 3.  The Value of Medicines: A Crucial but Vague Concept.

Authors:  Fernando Antoñanzas; Robert Terkola; Maarten Postma
Journal:  Pharmacoeconomics       Date:  2016-12       Impact factor: 4.981

4.  Could or Should We Use MCDA in the French HTA Process?

Authors:  Salah Ghabri; Jean-Michel Josselin; Benoît Le Maux
Journal:  Pharmacoeconomics       Date:  2019-12       Impact factor: 4.981

5.  Value-based reimbursement decisions for orphan drugs: a scoping review and decision framework.

Authors:  Mike Paulden; Tania Stafinski; Devidas Menon; Christopher McCabe
Journal:  Pharmacoeconomics       Date:  2015-03       Impact factor: 4.981

6.  Pharmaceutical Regulation in Central and Eastern European Countries: A Current Review.

Authors:  Paweł Kawalec; Tomas Tesar; Lenka Vostalova; Pero Draganic; Manoela Manova; Alexandra Savova; Guenka Petrova; Zinta Rugaja; Agnes Männik; Christoph Sowada; Ewa Stawowczyk; Andras Harsanyi; Andras Inotai; Adina Turcu-Stiolica; Jolanta Gulbinovič; Andrzej Pilc
Journal:  Front Pharmacol       Date:  2017-12-18       Impact factor: 5.810

7.  Determining the Value of Two Biologic Drugs for Chronic Inflammatory Skin Diseases: Results of a Multi-Criteria Decision Analysis.

Authors:  Néboa Zozaya; Lucía Martínez-Galdeano; Bleric Alcalá; Jose Carlos Armario-Hita; Concepción Carmona; Jose Manuel Carrascosa; Pedro Herranz; María Jesús Lamas; Marta Trapero-Bertran; Álvaro Hidalgo-Vega
Journal:  BioDrugs       Date:  2018-06       Impact factor: 5.807

8.  Utilization of multiple-criteria decision analysis (MCDA) to support healthcare decision-making FIFARMA, 2016.

Authors:  Julia I Drake; Juan Carlos Trujillo de Hart; Clara Monleón; Walter Toro; Joice Valentim
Journal:  J Mark Access Health Policy       Date:  2017-10-12

9.  HTA Implementation Roadmap in Central and Eastern European Countries.

Authors:  Zoltán Kaló; Adrian Gheorghe; Mirjana Huic; Marcell Csanádi; Finn Boerlum Kristensen
Journal:  Health Econ       Date:  2016-01-14       Impact factor: 3.046

10.  Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL).

Authors:  Lieven Annemans; Ségolène Aymé; Yann Le Cam; Karen Facey; Penilla Gunther; Elena Nicod; Michele Reni; Jean-Louis Roux; Michael Schlander; David Taylor; Carlo Tomino; Josep Torrent-Farnell; Sheela Upadhyaya; Adam Hutchings; Lugdivine Le Dez
Journal:  Orphanet J Rare Dis       Date:  2017-03-10       Impact factor: 4.123
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.